The company’s revenue from operation stood at Rs 13,786 crore which was up 10% versus Rs 12,525 crore posted in the corresponding quarter of the last financial year.
Sun Pharma‘s profit after tax (PAT) was up 6% on a sequential basis versus Rs 2,150 crore reported in Q4FY25, while the topline grew 8% compared to Rs 12,816 crore in the January-March quarter of Q4FY25.
Also Read: Adani Enterprises Q1 Results: Cons PAT plunges 45% YoY to Rs 976 crore; revenue drops 14%
The company reported expenses of Rs 10,325 crore in the quarter under review, which were 6% higher than Rs 9,762 crore reported in the year-ago period. The expenses grew 4% on a quarter-on-quarter basis versus Rs 9,956 crore reported in Q4FY25. The company spent on raw material, purchases of stock-in-trade, and employee benefits, among other things.
EBITDA
The Earnings Before Interest, Taxes, Depreciation and Amortisation (EBITDA) stood at Rs 4,302 crore, rising by 19.2% while the resulting EBITDA margin was at 31.1% in the reported quarter.
Sun Pharma Q1 Gross sales
The company’s gross sales, which grew 10% accounted for Rs 4,721 crore from the India formulation sales, gaining by 13.9%. The US formulation sales stood at $473 million, up 1.4%. Global Innovative Medicines sales stood at $311 million, up 16.9%, accounting for 19.3% of Q1FY26 sales. Commenting on the company’s earnings, Dilip Shanghvi, Chairman and Managing Director of the company, said that the company reported a strong performance during the quarter, where the overall growth reflects steady progress across all our markets. India continues to show strong momentum, contributing meaningfully to company’s performance, he added.
“The U.S. launch of LEQSELVI represents an important step forward, offering a new treatment option for patients with severe alopecia areata. LEQSELVI augments our portfolio in dermatology and adds a growth engine to our Innovative Medicines business,” Shanghvi said.
